Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

Blood Cancer Discov. 2024 May 1;5(3):146-152. doi: 10.1158/2643-3230.BCD-24-0022.

Abstract

While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit-risk assessment.

MeSH terms

  • Clinical Trials as Topic* / methods
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / therapy
  • Quality of Life
  • Research Design